ACE2 and COVID-19: Based on the available evidence, it is very plausible that patients with COVID-19 develop gastrointestinal symptoms attributed to the angiotensin converting enzyme-2 (ACE-2) receptor expressed in epithelial cells of the GI tract, which mediates direct viral entry and infection of the gastrointestinal tissue.